Ecosprin 150 Tablet

Effect

Ecosprin 150 Tablet reduces the renal clearance of methotrexate, leading to higher systemic exposure and increased risk of serious haematological toxicities such as bone marrow suppression and pancytopenia, especially at higher methotrexate doses.

Effect

Ecosprin 150 Tablet increases bleeding risk by three mechanisms: inhibition of platelet aggregation, irritation of the gastrointestinal mucosa, and displacement of anticoagulants from plasma protein binding sites.

Effect

Additive inhibition of platelet function significantly increases the risk of gastrointestinal or mucosal bleeding, especially in elderly patients or those with peptic ulcer history.

Effect

Ecosprin 150 Tablet reduces renal excretion of digoxin and lithium, resulting in increased plasma concentrations and risk of toxicity (arrhythmias for digoxin, neurotoxicity for lithium).

Effect

Ibuprofen may competitively inhibit Ecosprin 150 Tablet's access to platelet COX-1 receptors, reducing its antiplatelet (cardioprotective) effect when taken together frequently or at incorrect intervals.

Effect

Ecosprin 150 Tablet inhibits the uricosuric effect of these agents, potentially worsening hyperuricaemia and reducing efficacy in gout management.

Effect

Combined carbonic anhydrase inhibition may result in metabolic acidosis, confusion, lethargy, and other CNS side effects due to additive toxicity.

Effect

Co-administration increases nephrotoxic risk due to additive impairment of renal perfusion, particularly under dehydration or high-dose regimens.

Effect

Similar to valproate, Ecosprin 150 Tablet displaces phenytoin from protein-binding sites, potentially raising active drug levels despite unchanged total concentration.

Effect

Ecosprin 150 Tablet displaces valproate from its albumin binding sites, increasing the unbound (active) fraction without altering total serum levels, which may enhance therapeutic or toxic effects.